: The quadrivalent split influenza virus split vaccine, and the split influenza virus split vaccine for children under the age of 3, have not been approved for expansion of age groups.

On January 28, Zhifei Biological announced that its wholly-owned subsidiary Zhifei Longkema recently received a "Notice of Termination of Drug Registration Application" issued by the National Medical Products Administration, agreeing to withdraw the registration applications for children's quadrivalent split influenza virus vaccine and split influenza virus vaccine. Previously, Zhifei Biological submitted registration applications for these two children's influenza vaccines to the National Medical Products Administration in September and October 2024, respectively, and they were accepted for review.